Mehmet Asim Bilen
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Importance Reliable prognostic markers for immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC) remain limited. Objective To examine the impact of splenic volume change after ICI initiation on progression-free survival (PFS) and overall survival (OS) in patients with mRCC. Design A retrospective cohort study reviewing data from 2015 to 2023. Setting The Emory Kidney Cancer database (single-center academic instution). Participants Patients with mRCC who underwent first-line ICI treatment and had available abdominal imaging 30 days before and 60-120 days after ICI initiation. A total of 109 patients met inclusion criteria. Exposure Splenic volume change calculated as a percentage difference between baseline and follow-up imaging (median 2.8 months post-initiation) using a standardized formula, grouped into ≥10% increase and <10% increase. Main Outcomes and Measures Differences in OS and PFS assessed using Kaplan–Meier curves and multivariable Cox hazards regression models. Results A total of 109 patients met inclusion criteria. Median follow-up time was 25.2 months (IQR 11.2-41.5), during which there were 47 mortality events. Patients with a splenic volume increase ≥ 10% at a median 2.8 months after ICI initiation had worse 2-year PFS (28.5% vs 50.4%, P = .022) but not OS (69.4% vs 77.8%, P = .853) compared to patients with a < 10% increase in splenic volume. On multivariable analysis, a splenic volume increase ≥ 10% was independently associated with worse PFS (2.33 [95% CI 1.37-3.96], P = .002). Conclusions and Relevance In patients with mRCC, a splenic volume increase ≥ 10% at a median of 2.8 months following ICI initiation is independently associated with worse survival compared to an < 10% increase. Monitoring splenic volume changes may serve as a cost-effective radiographic prognostic marker to guide treatment sequencing.
Year:
2026
PURPOSE Accurate assessment of renal function is critical in the management of renal cell carcinoma (RCC), influencing surgical planning, systemic therapy eligibility, and clinical trial inclusion. Estimated glomerular filtration rate (eGFR) equations are commonly used in clinical practice but may not reflect true kidney function when compared with more accurate methods of determining renal function such as measured GFR using 24-hour urine creatinine clearance. METHODS In this prospective study, 72 patients with nonmetastatic RCC undergoing preoperative evaluation completed serum creatinine, cystatin C, and 24-hour urine collections. eGFR values were calculated using multiple established equations, both race-inclusive and race-neutral. The agreement between eGFR and measured GFR was assessed using Passing-Bablok regression. Linear regression estimated the discrepancy between eGFR and measured GFR at clinically relevant cutoffs of 45 and 60 mL/min/1.73 m 2 . RESULTS Across all equations, eGFR consistently overestimated renal function compared with measured GFR. At a measured GFR of 45, corresponding eGFR values ranged from 53 to 59 mL/min/1.73 m 2 ; at a measured GFR of 60, eGFR values ranged from 63 to 68 mL/min/1.73 m 2 . The greatest overestimation was observed with race-neutral Chronic Kidney Disease Epidemiology Collaboration 2021 equations. CONCLUSION eGFR equations significantly overestimate renal function in patients with renal masses when compared with 24-hour CrCl-derived measured GFR, particularly near clinically meaningful thresholds. This misclassification may result in inappropriate exposure to potentially harmful treatments, including nephrotoxic chemotherapy and radical nephrectomy. Confirmatory measured GFR testing should be considered in patients with renal function within a ±10 mL/min/1.73 m 2 range of clinically significant cutoff values to ensure accurate, safe, and appropriate therapeutic decision making. Clinical guidance should specify whether physicians should use eGFR or measured GFR when determining eligibility.
Year:
2025
PURPOSE Sarcomatoid renal cell carcinoma (sRCC) represents a kidney malignancy with a sarcomatoid component associated with poor prognosis. Immunotherapy (IO)-based combinations demonstrated promising activity in sRCC, yet real-world evidence (RWE) remains limited. We aimed to characterize the clinicopathologic features and outcomes of patients with metastatic sRCC treated with first-line immune-based combinations. PATIENTS AND METHODS This retrospective analysis from the ARON-1 study included 350 patients with histologically confirmed metastatic sRCC treated with first-line IO + IO, or IO + tyrosine kinase inhibitor across 66 centers in 21 countries (2016-2024). Overall survival (OS) was analyzed using Kaplan-Meier and Cox regression methods. Correlations between 2-year OS and clinical variables were assessed using Pearson's coefficient. RESULTS After a median follow-up of 19.1 months, median OS was 26.9 months (95% CI, 21.6 to 43.3). OS was longer in males (43.3 v 15.3 months in females; P < .001), in whom underwent nephrectomy (32.3 v 20.7 months; P = .002), and in patients without hepatic (32.3 v 15.3 months; P < .001), without skeletal (41.0 v 20.0 months; P = .007), or without lymph node metastases (43.3 v 24.6 months; P = .037). Median OS varied by International Metastatic RCC Database Consortium (IMDC) risk group: 66.5, 29.4, and 11.7 months in favorable-, intermediate-, and poor-risk patients, respectively ( P < .001). Different IO regimens showed variable outcomes by risk subgroup. Limitations include retrospective design and lack of central pathology review. CONCLUSION First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on the basis of baseline prognostic factors.
Year:
2025
Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DLL3), the activity of tarlatamab, a bispecific T-cell engager that directs cytotoxic T cells to DLL3-positive (DLL3+) cells, was evaluated in the DeLLpro-300 study (NCT04702737). Patients and Methods: This was a phase 1b, open-label study evaluating tarlatamab monotherapy in patients with metastatic de novo or treatment-emergent NEPC defined by histologic, genomic, or IHC criteria. Tarlatamab was administered intravenously every 2 weeks at a dose of 100 mg with a 1-mg step dose. The primary objective was safety, and a secondary objective was objective response rate (ORR) per RECIST v.1.1; DLL3 expression was retrospectively assessed by IHC. Results: Forty patients were enrolled (DLL3+ tumors, n = 18; DLL3− tumors, n = 14; and DLL3 unknown tumors, n = 8). The most common treatment-related adverse events were cytokine release syndrome (82.5%), dysgeusia (42.5%), and decreased appetite (40.0%). Cytokine release syndrome was predominantly of low grade (grade 1/2/3/4+, 62.5%/15%/5%/0%), occurred exclusively in cycle 1, and was transient in duration (median duration, 3 days). The ORR was 10.5% [95% confidence interval (CI), 2.9–24.8]; the median duration of response was 7.3 months in the overall cohort. Patients with DLL3+ tumors (vs. patients with DLL3−/DLL3 unknown tumors) achieved a higher ORR [22.2% (95% CI, 6.4–47.6) vs. 0% (95% CI, 0–15.4)] and radiographic progression-free survival rate at 6 months [27.7% (95% CI, 8.7–50.9) vs. 0%]. Conclusions: The DeLLpro-300 study provides preliminary evidence for the safety and antitumor activity of tarlatamab in DLL3+ NEPC.
Year:
2025
Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DLL3), the activity of tarlatamab, a bispecific T-cell engager that directs cytotoxic T cells to DLL3-positive (DLL3+) cells, was evaluated in the DeLLpro-300 study (NCT04702737). Patients and Methods: This was a phase 1b, open-label study evaluating tarlatamab monotherapy in patients with metastatic de novo or treatment-emergent NEPC defined by histologic, genomic, or IHC criteria. Tarlatamab was administered intravenously every 2 weeks at a dose of 100 mg with a 1-mg step dose. The primary objective was safety, and a secondary objective was objective response rate (ORR) per RECIST v.1.1; DLL3 expression was retrospectively assessed by IHC. Results: Forty patients were enrolled (DLL3+ tumors, n = 18; DLL3− tumors, n = 14; and DLL3 unknown tumors, n = 8). The most common treatment-related adverse events were cytokine release syndrome (82.5%), dysgeusia (42.5%), and decreased appetite (40.0%). Cytokine release syndrome was predominantly of low grade (grade 1/2/3/4+, 62.5%/15%/5%/0%), occurred exclusively in cycle 1, and was transient in duration (median duration, 3 days). The ORR was 10.5% [95% confidence interval (CI), 2.9–24.8]; the median duration of response was 7.3 months in the overall cohort. Patients with DLL3+ tumors (vs. patients with DLL3−/DLL3 unknown tumors) achieved a higher ORR [22.2% (95% CI, 6.4–47.6) vs. 0% (95% CI, 0–15.4)] and radiographic progression-free survival rate at 6 months [27.7% (95% CI, 8.7–50.9) vs. 0%]. Conclusions: The DeLLpro-300 study provides preliminary evidence for the safety and antitumor activity of tarlatamab in DLL3+ NEPC.
Year:
2025
Non-clear cell renal cell carcinomas (nccRCC) comprise a heterogeneous group of rare malignancies, accounting for approximately 20% of all kidney cancers. Given the rarity of these diverse subsets of RCC, the treatment paradigm for nccRCC is often based on treatment strategies utilized in the management of clear cell renal cell carcinoma (ccRCC), which may not fully address the distinct molecular and genetic drivers unique to nccRCC tumors. However, recent advances in the molecular characterization of nccRCC have led to the identification of new therapeutic targets, resulting in the development of more targeted therapies for nccRCC treatment. Furthermore, the role of molecular characterization of renal tumors is emphasized in the 2022 World Health Organization reclassification of genitourinary tumors, given that delineation of renal tumor subtypes now also relies on genetic markers. In order to highlight this evolving treatment landscape, our review provides a comprehensive summary of recent progress related to the biology and management of nccRCC subtypes.
Year:
2025
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of nonimmune cells related to, related to Figure 4. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other nonimmune clusters.
Year:
2025
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of myeloid cells, related to Figure 4. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other myeloid clusters.
Year:
2025
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of T cells, related to Figure 5. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other T cell clusters.
Year:
2025
Differential gene expression analysis based on bulk RNA-seq, including differentially expressed genes for patients with complete or partial response compared to patients with progressive disease, related to Figure 2. Positive log fold-change indicates upregulation in responders.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (28)
David Braun
Assistant Professor, Principal Investigator
Yale University Yale Cancer Center
Hiroji Uemura
Yokohama Kokuritsu Daigaku
Michael Charles Lowe
Emory University
Bassel Nazha
Emory University School of Medicine
Matthew Rettig
Professor
University of California, Los Angeles
David Einstein
Beth Israel Deaconess Medical Center
Viraj A. Master
Professor
Emory University
Toni Choueiri
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Kenneth Ogan
Professor of Urology
Emory University Hospital
Sebastiano Buti
Ricercatore a contratto tipo B
University of Parma
Lisa Horvath
Conjoint Professor of Medical Oncology (Genitourinary Cancer)
University of Sydney
Mark Stein
Associate Professor
Columbia University Irving Medical Center
Michael Hurwitz
Associate Professor
Yale University School of Medicine
Se Hoon Park
Professor
Sung Kyun Kwan University School of Medicine at Samsung Medical Center Cancer Center
Ben Tran
Peter MacCallum Cancer Institute
Vikram Narayan
Assistant Professor
Emory University
Kelly Street
Assistant Professor
University of Southern California Keck School of Medicine
Christopher Friese
Professor
University of Michigan School of Nursing
Ana Aparicio
Professor
The University of Texas MD Anderson Cancer Center
Shahneen Sandhu
-
Ondrej Fiala
Charles University
R. Donald Harvey
Emory University School of Medicine
Rahul Aggarwal
University of California
Yuan Liu
Research Associate Professor
Emory University
Tanya Dorff
Associate Professor
City Of Hope National Medical Center
Naomi B Haas
PI
University of Pennsylvania
David McDermott
Beth Israel Deaconess Medical Center
Martijn Lolkema
Head of Department a.i
Erasmus MC
Make your next move.
Prepare your application
Review drafts before you send them.